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Abstract 
Cardiopulmonary late toxicity are of concern in concurrent chemoradiotherapy (CCRT) for 
esophageal cancer. The aim of the study was to examine the benefit of proton beam therapy (PBT) 
using clinical data and adaptive dose-volume histogram (DVH) analysis. Subjects were 44 patients 
with esophageal cancer who underwent definitive CCRT using X-rays (n=19) or protons (n=25). 
Experimental recalculation using protons was performed for the patient actually treated with X-rays, 
and vice versa. Target coverage and dose constraints of normal tissues were conserved. Lung V5-V20, 
mean lung dose (MLD), and heart V30-V50 were compared as risk organ doses between 
experimental plans and actual treatment plans. Potential toxicity were estimated using protons in 
patients actually treated with X-rays, and vice versa. Pulmonary events of grade ≥2 occurred in 8/44 
cases (18%) and cardiac events were seen in 11 cases (25%). Risk organ doses in patients with events 
of grade ≥2 were significantly higher than those with events of grade ≤1. Risk organ doses were lower 
in proton plans compared to X-ray plans. All patients suffering toxicity who were treated with X-rays 
(n=13) had reduced predicted doses in lung and heart using protons, while doses in all patients treated 
with protons (n=24) with toxicity of grade ≤1 had worsened predicted toxicity with X-rays. Analysis 
of normal tissue complication probability showed potential reduction of toxicity using proton beams. 
Irradiation dose, volume and adverse effects on heart and lung can be reduced using protons. Thus, 
PBT is a promising treatment modality in management of esophageal cancer. 
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Introduction 
Surgery is the standard treatment for esophageal cancer, but concurrent chemoradiotherapy 
(CCRT) has benefits with regard to prognosis, mortality and quality of life after treatment (1-3). 
Outcomes of CCRT are promising, but late adverse events in the heart and lung are of concern, with 
reported risks of adverse effects of grade ≥3 of 6% to 46% (2-6). Reduction of irradiation doses to the 
organ at risk (OAR) is a simple and robust method to reduce the rate of adverse events. In this context, 
proton beam therapy (PBT) may provide therapeutic advantages over conformal X-ray therapy for 
patients with esophageal cancer (7, 8). These advantages are based on the fundamental physical dose 
distribution of particle-ion beams (9). Compared to 4D intensity-modulated radiation therapy (IMRT), 
PBT reduces lung V5, V10, V20 and the mean lung dose (MLD) in dosimetric studies (8). Thus, 
previous reports have shown theoretical therapeutic advantages of PBT (7, 8), but a correlation 
between the dose advantage and clinical outcome has not been established. 
A further problem of previous studies using dose-volume histogram (DVH) analysis is that 
anatomical changes and planning re-evaluation during fractionated radiation are not taken in count. 
Simple summation of DVH data between different computed tomography (CT) scans does not reflect 
the true DVH, particularly when beam directions are changed. An adaptive DVH analysis that reflects 
close to the true dose-volume relationship is needed by utilization of CT-CT deformation techniques. 
In this study, by cross-referencing treatment plans for each patient using adaptive DVH analysis and 
the actual incidence of adverse effects, we compared the possible adverse effects of X-rays with those 
in PBT. Then, using normal tissue complication probability (NTCP) calculations, we examined the 
potential therapeutic advantages of PBT over X-rays. 
 
1. Materials and Methods 
1.1. Patients 
Consecutive patients who underwent definitive CCRT utilizing X-rays (n=19) or protons (n=25) 
between 2009 and 2011 were enrolled in the study. Patient characteristics are shown in Table 1. 
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Staging evaluation of each patient was done with upper GI series, CT scans, 
esophagogastroduodenoscopy (EGD), and positron emission tomography (PET) / CT scans. 
Endoscopic ultrasound was also used if the depth of invasion was unclear. The X-ray group included 
more advanced stage cases than the proton group. The median dose of radiation was 60 Gy in both 
groups. Most tumor sites were in the thoracic esophagus and all tumors were squamous cell 
carcinoma. 
Immediately after the start of radiotherapy, all patients received the first cycle of chemotherapy. 
This consisted of intravenous infusion of cisplatin 70 mg/m2 body surface area over 3 hours followed 
by fluorouracil 2800 mg/m2 over 96 hours. Therefore, concurrent chemotherapy was administered 
during days 1 to 5 of radiotherapy. Additional cycles of chemotherapy were scheduled at 3-week 
intervals. Thus, patients received 2 cycles of chemotherapy during fractionated radiotherapy. Patients 
in the X-ray group were treated with only X-rays and chemotherapy, and those in the proton group 
were treated with only protons and the same chemotherapy regimen. Thus, no patient received a 
combination of X-rays and proton beams. 
 
1.2. Radiotherapy systems 
The X-ray therapy system consisted of a linear accelerator (Clinac iX, Varian Medical Systems, 
Palo Alto, CA, USA) equipped with a 5-10 mm multileaf collimator (MLC), a rotational treatment 
couch, and a treatment-planning system (Xio ver. 4.8, Elekta, Stockholm, Sweden). The PBT system 
consisted of a 250 MeV synchrotron equipped with an isocentric rotational gantry, a 15×15 cm passive 
scattering port with a 5 mm MLC, a rotational treatment couch, and a treatment-planning system 
(Hitachi 3D Treatment Planning System ver. 2.0, Tokyo, Japan), a treatment-planning CT scanner, and 
an X-ray simulator without any system modification. 
 
1.3. Principles of treatment planning 
The gross tumor volume (GTV) was defined as all diseased tissue seen on CT images and other 
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diagnostic imaging. To confirm the tumor location on CT, two to three metal markers were placed in the 
normal esophageal wall at the tumor edges during endoscopy prior to the initial treatment planning. The 
initial clinical target volume (CTV1) included all areas of potential disease spread, such as the 
esophageal wall and mediastinal lymph nodes. For cancer of the thoracic esophagus (n=34), the whole 
thoracic esophagus was included in CTV1 in most patients. The second CTV (CTV2) included the 
GTV with 20- to 25-mm margins in the cranial and caudal directions of the tumor and 10-mm margins 
in other directions. The lung contour was defined as the thoracic cavity excluding the bilateral main 
bronchus. The heart contour was defined as described by Feng et al. (10). In brief, superiorly the heart 
starts just inferior to the left pulmonary artery. For simplification, a round structure including the great 
vessels was contoured. Inferiorly, the heart blends with the diaphragm. The superior vena cava was 
included for simplification and consistency. 
A total dose of 40 gray (Gy) or gray equivalent (GyE), with relative biological effectiveness 
(RBE) set to 1.1 for proton, was given to CTV1 with conventional fractionation with a fractional dose 
of 2 Gy. An additional dose of 20 Gy or GyE in 10 fractions was given to CTV2. The planning target 
volume (PTV) was made by adding adequate margins to the CTVs. The total dose was 60 Gy in most 
patients; however, 5 patients in the proton group received an additional boost for GTV with a short 
margin, since an endoscopic examination at a total dose of 50 Gy suggested persistent tumor tissue. If 
necessary, treatment plans were revised repeatedly to adapt to tumor volume changes and patient 
constitutional changes. Replanning was performed using new planning CT scans. 
For X-ray planning, a two-field anteroposterior and posteroanterior (AP/PA) beam arrangement 
was used for CTV1 up to 40 Gy, and then a two-field right anterior oblique (RAO) and left posterior 
oblique (LPO) arrangement was used for the boost to CTV2. Field in field techniques and wedge 
compensators were sometimes used to maintain dose distribution uniformity. For PBT planning, a 
two-field AP/PA beam arrangement was used throughout treatment in most thoracic cases. When 
spinal cord doses became an issue, even in PBT, an LPO arrangement was used instead of a PA 
arrangement. RAO and left anterior oblique arrangements were used in cervical cases. In cases where 
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the PTV exceeded the maximum field size (14 cm) in our system, two fields were “patched” using the 
D-SLIT technique (11). All plans were revised and approved by multiple radiation oncology specialists 
with experience in particle therapy and X-ray therapy. 
 
1.4. Experimental planning and cross referencing 
Experimental PBT plans were made for patients who received X-ray therapy, using the actual 
planning CT. Alternatively, X-ray plans were made using the planning CT for patients who received 
PBT. Original CTVs and PTVs used in the actual treatment were maintained in the experimental plans. 
To evaluate cumulative dose and volume from different planning CTs accurately, all planning CTs and 
doses linked to CT images were merged using deformation techniques (12-14). Data conversion and 
translation between systems, CT-CT deformation, and dose volume studies were performed using 
MIM Maestro ver. 6 (Cleveland, OH, USA). The concept of dose delivery to the target and normal 
tissue was exactly the same in X-ray and proton planning. Coverage of PTVs was provided by >95% 
of prescribed doses and the maximum spinal dose was restricted up to 44 Gy. After summation of each 
X-ray and proton treatment plan, dosimetric factors such as % volume of whole lung, heart receiving 
more than a certain dose (Vx), and the mean lung dose (MLD) were calculated using DVH analysis. 
The experimental plans were compared with the actual treatment plans. Typical dose distributions and 
total DVH for X-rays and protons are shown in Figure 1. 
 
1.5. Normal Tissue Complication Probability calculation 
Normal tissue complication probability (NTCP) was calculated using the Lyman-Kutcher-Burman 
(LKB) model following Emami et al. and Burman et al. (15-17):  
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where TD is the tolerance dose and v is the fraction of organ irradiated. The model has 4 parameters: 
Vref, TD50, n and m. TD50 is the dose to the whole organ that gives a complication probability of 50%. 
Volume dependence is determined by n, the slope of the complication probability vs. dose curve is 
determined by m, and Vref is the reference volume for TD50. 
 
1.6.  Follow up 
Follow-up included physical examinations, blood tests and imaging studies. Squamous cell 
carcinoma antigen was measured as a serum tumor marker at 1 month after completion of radiotherapy 
and at 2- to 3-month intervals thereafter. EGD and CT scans were performed at 1 to 2 months after 
radiotherapy for assessment of initial tumor response. Similar scans were performed every 3 months 
for the first year and every 6 months thereafter for evaluation of tumor recurrence at lymph nodes and 
distant organs. Treatment-related morbidities were evaluated by physical examination and imaging. 
Events was assessed using the National Cancer Institute Common Terminology Criteria for Adverse 
Effects (CTCAE), ver. 4. 
 
1.7.  Statistical analysis 
 Statistical analysis was performed by Student t-test or paired t-test using R Project software 
(http://www.r-project.org/). Receiver operating characteristic (ROC) curves and specificity / sensitivity 
calculations were also performed using this software. 
 
2. Results 
2.1.  Adverse effects 
Cardiopulmonary late adverse effects of grade ≥2 in all 44 patients are shown in Table 2. 
Pulmonary events of this grade occurred in 8 cases (18.2%) and cardiac events such as pericardial 
effusion occurred in 11 cases (25.0 %). All pulmonary events of grade ≥2 were in the X-ray group. 
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Cardiac events of grade ≥2 occurred in 10 cases (52.6 %) in the X-ray group and in 1 case (4.0%) in 
the proton group. Six cases in the X-ray group had both pulmonary and cardiac events of grade ≥2. 
 
2.2.  Correlation of DVH parameters and adverse effects 
DVH parameters such as Vx and MLD for patients with and without adverse events of grade ≥2 
are shown in Figure 2. The irradiated OAR volume in patients with events of grade ≥2 was 
significantly higher than those in events of grade ≤1. The data were used to calculate ROC curves, 
which gave cut-off values of V5 44.1% (specificity 93.1%, sensitivity 69.2%), V10 31.5% (93.1%, 
69.2%), V20 22.5% (93.1%, 69.2%), and MLD 9.78 Gy (86.2%, 76.9%) for the lung; and V30 35.0% 
(86.2%, 76.9%), V40 27% (86.2%, 76.9%), and V50 18.9% (89.7%, 69.2%) for the heart. 
 
2.3.  DVH parameters in the organ at risk based on cross referencing of treatment plans 
Dose-volume data in actual and experimental treatment plans are shown in Table 3. Lung V5-V20, 
MLD, and heart V30-V50 were all lower in PBT plans (p<0.001 by paired t-test). The X-ray group 
included more cases with advanced disease, but experimental dose-volume data calculated for protons 
were mostly the same as actual data in the proton group. Similarly, experimental dose-volume data 
calculated for X-rays in the proton group were mostly the same as actual data in the X-ray group. 
Differences in DVH parameters in actual treatment and experimental plans in each group are shown in 
Figure 3. All patients in the X-ray group had reduced irradiated lung and heart volumes using protons 
(p<0.001), while irradiation exposure worsened using X-rays in all patients in the proton group 
(p<0.001).  
 
2.4.  Potential change in dose distribution 
DVH parameters for proton treatment in patients in the X-ray group with adverse events of grade 
≥2 are shown in Figure 4. There were 13 cardiopulmonary late adverse events of grade ≥2 in this 
group and dose parameters decreased in all these cases in experimental proton plans. In the proton 
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group, 24 cases had cardiopulmonary adverse events of grade ≤1 and the mean values of all 
parameters increased in all these patients in X-ray plans.  
 
2.5. Calculated normal tissue complication probability (NTCP) 
 Changes in NTCP for the lung and heart in each patient are shown in Figure 5. NTCP decreased 
in proton plans in the X-ray group and increased in X-ray plans in the proton group. No case had an 
increased NTCP in proton plans or a decreased NTCP in X-ray plans.  
 
3. Discussion 
Three-dimensional conformal radiation therapy (3D-CRT) using X-rays is a widely used technique 
worldwide. However, X-ray treatment of esophageal cancer results in large parts of the heart and lung 
being irradiated at low to medium doses (18, 19) and this causes late adverse events in these organs 
[2-6]. Ishikura et al. reported a rate of 11.5 % for late cardiopulmonary toxicity of grade ≥3 and the 
RTOG 85-01 and Intergroup 0123 studies found rates of 28% and 37% to 46%, respectively, for any 
severe late toxicity of grade ≥3.  
IMRT can be used to focus high dose areas to the target, which leads to lower heart doses (20) and 
fewer cardiac late adverse events. The clinical superiority of IMRT over 3D-CRT has been suggested 
using propensity scores (21). However, the basic physical characteristics of X-rays of multiple field 
directions leads to wider low dose areas and IMRT results in irradiation of larger areas at low doses 
than 3D-CRT; this is especially critical in organs with low tolerance doses, such as the lung (22). The 
risk of pneumonitis may also be higher with IMRT in thoracic irradiation (23, 24). Additionally, IMRT 
is considered unsuitable for treatment of cancer with respiratory movement because it is difficult to 
apply respiratory gating during IMRT because of the complicated beam arrangement. 
PBT provides distinct therapeutic advantages over 3D-CRT for esophageal cancer based on DVH 
studies (7, 8) because it is possible to reduce OAR doses without affecting the PTV coverage of the 
prescribed dose. Compared to 4D IMRT, PBT can reduce V5, V10, V20 and MLD from 49.5% to 
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13.9%, 32.5% to 12%, 15.6% to 9.8%, and 9.65 Gy to 4.55 Gy, respectively (8). However, previous 
DVH studies have not examined the correlation with treatment outcomes in esophageal cancer. The 
current study provides a link of the dose distribution superiority of PBT with actual clinical results by 
cross-referencing of individual patient plans. 
In this study, morbidity rates in the heart and lung in the proton group were lower than those in the 
X-ray group, consistent with the lower OAR doses and volumes in the proton group. However, there 
were more advanced cases in the X-ray group than in the proton group, and this may have affected 
morbidity rate. Previous phase II studies of definitive radiation therapy of 60 Gy/ 30 fr concurrently 
combined with CDDP and 5-FU for advanced esophageal cancer (JCOG 9906) revealed that late 
toxicities compromised grade 3 or severe pericardial (13%) and pleural effusions (9%) and radiation 
pneumonitis (4%) (25). Furthermore, results of a randomized phase II study for stage II-IVA 
esophageal cancer was recently reported by Nishimura (26), and 91 patients were treated with 
radiation therapy of 60 Gy/ 30fr concurrently combined with CDDP plus 5FU. In the study, grade 3 or 
severe late toxicities of pericardial and pleural effusions were observed in 9% and 7%, respectively, 
but the corresponding rates of a phase II study (JCOG9708) performing CCRT using a similar 
treatment protocol for stage I esophageal cancer were 0% and 3%, respectively (27). Therefore, there 
seems to be no doubt that the size of irradiation fields affects development of late cardiopulmonary 
toxicities.  
In our study however, 11 of 14 patients with Stage IIIA-C in the X-ray group experienced grade 2 
or severe cardiopulmonary events, whereas none of 9 patients with Stage IIIA-C in the proton group 
did. Although some lung dose parameters of X-ray plans in the proton group were lower than in the 
X-ray group, no significant difference in OAR doses between the two groups were observed. 
Furthermore, experimental dose-volume data calculated for protons in the X-ray group were 
mostly the same as actual data in the proton group. Similarly, experimental dose-volume data 
calculated for X-rays in the proton group were mostly the same as actual data in the X-ray group 
(Figure 3). In addition, we also found a clear correlation between OAR doses and late adverse events 
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in the present study. Therefore, we think that differences in incidences of the cardiopulmonary events 
between X-ray and proton therapy in the study may be mainly caused by the difference in dose 
distribution of different types of radiation beams. 
NTCP is a useful method for estimating adverse effects in radiotherapy. In this study, we 
calculated NTCP using the model described in Burman et al. (17) using data from Emami et al. (16). 
However, the rates of observed adverse events in chemoradiotherapy were higher than those expected 
from the calculated NTCP. The data in Enami et al. (16) were obtained from studies using radiotherapy 
alone and this may explain why we observed more adverse events than expected from the calculated 
NTCP. Definitive radiotherapy often includes concurrent chemotherapy, and thus parameters reflecting 
this approach are in demand. 
Clinically, new planning CTs are obtained when tumors shrink during radiotherapy. This makes it 
difficult to evaluate the cumulative doses accurately for two plans based on different CT series. Simple 
accumulation of DVH data does not reflect the true DVH, particularly when beam directions are 
changed. To evaluate the cumulative DVH as accurately as possible and to reflect actual 
time-dependent changes of the patient and tumor, we used a CT-CT deformation technique reported in 
adaptive RT and four-dimensional CT studies (12-14). Therefore, more accurate DVHs of OARs were 
obtained in this study compared with previous studies that did not utilize this deformation technique.  
This study does not directly show superiority of PBT over X-rays because it is a non-randomized 
retrospective study. However, by cross-referencing proton and X-ray plans, we believe that bias has 
been reduced to a minimal level. Thus, the superiority of PBT for esophageal cancer with regard to 
irradiation doses to the heart and lung and occurrence of cardiopulmonary adverse effects is apparent 
from the results of the study. Accumulation of cases is required to validate this result, in part because 
our NTCP data underestimate the risk of adverse effects due to the small sample size and use of 
chemoradiotherapy data. 
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Figure Legends 
Figure 1. Typical dose distributions and dose volume histograms in treatment of esophageal 
cancer in (A) X-ray 3D-CRT and (B) PBT. In 3D-CRT, 20 Gy is delivered widely to the lung, 30 Gy 
is delivered to most of the heart, and 60 Gy is also delivered widely to the heart. (C) Typical dose 
volume histograms of the lung and heart. PBT results in lower irradiation doses in both OARs. 
 
Figure 2. Parameters in patients with and without adverse events of grade ≥2. All parameters 
were significantly higher in patients with late adverse events of grade ≥2. Bars show the median and 
95%CI. Horizontal bars show cut-off lines calculated from ROC curves. 
 
Figure 3. Differences in parameters in the lung and heart in actual treatment plans and 
experimental plans. All dose parameters were significantly lower in PBT (p<0.001 by paired t-test). 
Horizontal bars show median values and vertical bars show the 95%CI.  
 
Figure 4. Potential changes in parameters in patient with adverse effects of grade ≥2 in the X-ray 
group and in patients with adverse effects of grade ≤1 in the proton group. Horizontal bars show 
cut-off lines calculated from ROC curves. 
 
Figure 5. Normal tissue complication probability (NTCP) changes between plans in the X-ray 
and proton groups. 
 X-ray group Proton group 
Number of patients 19 25 
Alive/Dead 13/6 20/5 
Median Follow-Up Period 20M (+/- 4.7M 95%CI) 24M (+/- 5.1M 95%CI) 
Irradiated Dose 60Gy 60-70GyE (Median 60Gy) 
Site  Cervical 7 3 
 Thoracic 12 22 
 Abdominal 0 0 
Stage （UICC 7th）    
0 0 1 
IA 4 7 
IB 0 3 
IIA 0 1 
IIB 1 4 
IIIA 4 3 
IIIB 4 1 
IIIC 6 5 
Table1 : Characteristics of the enrolled patients. 
All data ≤G1 G2 G3 G4 G5 
Pharmacological Pneumonitis 43 (97.7%) 0 0 0 1 (2.3%) 
Lung Infection 43 (97.7%) 0 0 0 1 (2.3%) 
Radiation Pneumonitis 40 (90.9%) 3 (9.1%) 1 (2.3%) 0 0 
Pulmonary Effusion 42 (95.5%) 1 (2.3%) 1 (2.3%) 0 0 
Pericardial Effusion 33 (75.0%) 11 (25.0%) 0 0 0 
 
X-ray group ≤G1 G2 G3 G4 G5 
Pharmacological Pneumonitis 18 (94.7%) 0 0 0 1 (5.3%) 
Lung Infection 18 (94.7%) 0 0 0 1 (5.3%) 
Radiation Pneumonitis 15 (78.9%) 3 (15.8%) 1 (5.3%) 0 0 
Pulmonary Effusion 17 (89.5%) 1 (5.3%) 1 (5.3%) 0 0 
Pericardial Effusion 9 (47.4%) 10 (52.6%) 0 0 0 
 
Proton group ≤G1 G2 G3 G4 G5 
Pharmacological Pneumonitis 25 (100%) 0 0 0 0 
Lung Infection 25 (100%) 0 0 0 0 
Radiation Pneumonitis 25 (100%) 0 0 0 0 
Pulmonary Effusion 25 (100%) 0 0 0 0 
Pericardial Effusion 24 (96.0%) 1 (4.0%) 0 0 0 
Table 2: Clinical outcomes for adverse effect. 
X-ray group 
  Actual X-ray Plan (95%CI)   Experimental Proton Plan (95%CI)    
Lung V5 45.57 
 
(40.64-50.50) 
 
18.89 
 
(16.90-20.88) 
 
p=1.48*10-10 
Lung V10 33.36 
 
(28.68-38.04) 
 
15.51 
 
(13.87-17.15) 
 
p=2.15*10-8 
Lung V20 23.98 
 
(20.56-27.40) 
 
10.61 
 
(9.36-11.86) 
 
p=8.35*10-9 
MLD 12.69 
 
(11.03-14.35) 
 
4.72 
 
(4.12-5.32) 
 
p=3.84*10-10 
Heart V30 65.03 
 
(48.58-81.48) 
 
18.84 
 
(11.26-26.42) 
 
p=9.10*10-4 
Heart V40 55.65 
 
(40.13-71.17) 
 
9.54 
 
(4.42-14.66) 
 
p=1.41*10-4 
Heart V50 18.89 
 
(10.33-27.45) 
 
5.41 
 
(1.65-9.17) 
 
p=4.70*10-3 
 
Proton group 
  Actual proton Plan (95%CI)   Experimental X-ray Plan (95%CI) 
 
  
Lung V5 19.56 
 
(22.29-16.83) 
 
34.30 
 
(29.89-38.71) 
 
p=1.75*10-8 
Lung V10 16.77 
 
(14.33-19.21) 
 
26.77 
 
(23.12-30.42) 
 
p=8.01*10-7 
Lung V20 12.54 
 
(10.44-14.64) 
 
19.58 
 
(16.83-22.33) 
 
P=5.90*10-5 
MLD 5.73 
 
(4.73-6.73) 
 
9.32 
 
(8.03-10.61) 
 
p=6.39*10-6 
Heart V30 21.51 
 
(16.94-26.08) 
 
63.29 
 
(52.43-74.15) 
 
p=8.22*10-8 
Heart V40 15.29 
 
(11.74-18.84) 
 
51.78 
 
(41.45-62.11) 
 
p=7.53*10-7 
Heart V50 5.51 
 
(2.63-8.39) 
 
28.96 
 
(21.54-36.38) 
 
p=2.62*10-4 
Table 3: DVH parameters in both actual treatment and experimental planning.  
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